跳至主要内容
临床试验/IRCT2014091418745N2
IRCT2014091418745N2已完成2 期

anocurcumin role as an adjunctive therapy on treatment response and quality of life in patients with breast and gastrointestinal cancer resistant to treatment: Randomized clinical trial

Vice-?hancellor for Research of Tehran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 70 years(—)
性别
All

入选标准

  • Randomize; Pathology report of invasive breast and GI carcinoma; signed informed consent; resistant to treatment; metastatic disease.
  • Exclusion criteria: Less than 50% heart ejection fraction; heart failure; liver failure (liver enzymes more than 5 times of upper normal limit) or creatinine more than 2 mg/dl; low albumin<2; brain metastasis; sever diarrhea.

排除标准

  • 未提供

研究者

发起方
Vice-?hancellor for Research of Tehran University of Medical Sciences

相似试验